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Abstract 
The field of regenerative and reparative medicine is an expanding and rapidly growing one. In 
order to create cell-based therapies it is crucial to standardize techniques and establish 
protocols.  
The purpose of this study was to establish cryopreservation and thawing protocols of animal 
cells as well as to evaluate the viability loss of mesenchymal stem cells upon thawing, and up to 
72 hours later under three different environmental conditions. 
Using the trypan blue method, cell viability was determined under three different temperature 
settings post-thaw: room temperature at 21ºC, incubation at 37ºC and refrigeration at 4ºC for up 
to 72 hours. The preservation of the cells in plastic and glass vials was also compared as well 
as the thaw method using human umbilical cord plasma and canine serum. 
It was possible to determine that there was no difference in cell viability results between the use 
of fetal bovine serum and human umbilical cord blood plasma at either 90 or 95%, as medium 
supplements during cryopreservation, which also enables the use of only 5 to 10% dimethyl 
sulfoxide.  
On the other hand, canine serum does not serve as an appropriate protein source during 
thawing since it causes cellular agglomeration resulting in lower viabilities. 
Results also show that the material of the vials used to preserve cells post thaw does not 
influence viability significantly, whereas the temperature at which they are conserved does. 
Refrigeration at 4ºC appears to be the preferable temperature for maintenance of these cells 
post-thaw.  
Nonetheless, there is still room for protocol improvement since many questions remain 
unanswered and much work is needed to be done in the laboratory and the clinic to understand 
how to fully apply these cell-based therapies to treat disease. 
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I. INTRODUCTION 
As in human medicine, the search for ways to increase longevity in animal species and 
maintaining their health has gained increasing interest in veterinary medicine studies and 
advances. Mechanisms of natural and biological repair (both in physical damage as well as in 
illness) of living organisms using cells and tissues are of most interest.  
During the 19th century, it was postulated that certain tissues, comprised of short-lived cells, had 
the ability to self-renew for the lifetime of an organism. Research advanced and culminated in 
the discovery of stem cells. This capacity to differentiate into specialized cells makes stem cells 
valuable in therapeutic applications designed to regenerate and repair cellular or tissue 
damage. This discovery opened a whole new realm of possibilities in the field of biological 
repair offering new potential for treating diseases as a result of those unique regenerative 
abilities (Ramalho-Santos & Willenbring, 2007; Bianco et al., 2008). These were the early days 
of regenerative medicine. 
Since then and to this day, there has been a rapid growth in this field, accelerating in the last 30 
years and expanding from research to clinical trials (Dominici et al., 2006). Regenerative 
medicine as a cell-based therapy refers to therapeutic approaches in which stem cells are 
induced to differentiate under controlled conditions to be later injected into or transferred to a 
patient to repair damaged or destroyed cells or tissues (Lane et al., 2014; Mao & Mooney, 
2015). Here lies the potential to not only treat, but cure disease. 
Specific and consistent protocols for the preparation and application of such therapies in 
preclinical research, clinical trials and final treatments are essential (Heathman et al., 2015). 
Protocols for mesenchymal stem cell cryopreservation and thawing processes remain 
suboptimal and inconsistent (Ikebe & Suzuki, 2014). Following this concept, the final aim of this 
study was to determine cellular number and viability loss of mesenchymal stem cells after 
undergoing a cryopreservation and thawing process and possibly perfect these protocols. The 
number of cells lost during these processes could then be taken into account when determining 
the number of viable cells needed to be cryopreserved, according to the final number of cells 
required for a given treatment. Post-thaw loss over time was also determined. 
Although this field is advancing at a hasty pace, there are still a few obstacles that must be 
overcome for the application of certain cell-based therapies, such as ethical and legal questions 
due to the use of embryonic stem cells, particularly human, and the conduction of stem 
research in general (Hyun, 2010). 
In this study, only mesenchymal stem cells (MSCs) obtained from postnatal animals were used. 
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II. LITERATURE REVIEW 
1. Regeneration in nature 
Regeneration and repair processes are naturally observed in humans and animals. These 
processes can also be found in plants and simpler animals, such as planaria and crayfish as 
well as in embryos (Metcalfe & Ferguson, 2007; Gurtner et al., 2008; Wagner et al., 2011; 
Rouhana & Tasaki, 2016). 
Planarians are flat, soft-bodied worms that have evolved a remarkable stem cell regenerative 
system, giving them the ability to rapidly self-renew the entire animal within a matter of weeks 
(Wagner et al., 2011; Rink, 2013). Crayfish, on the other hand, have the ability to shed or sever 
an appendage to escape predators and then regenerate it (Juanes & Smith, 1995; Cooper, 
1998; Maginnis, 2006). There is a cost that comes with this process as discussed by Maginnis 
2006. 
In nature, there appears to be a reverse relationship between complexity and regenerative 
ability; the more complex the organism, the more decreased its capacity for regeneration is. 
Tissue and organ regeneration in postnatal mammals is more limited than that found in more 
basic animals, and different tissues have different renewal abilities. The gut, blood, epidermis 
and liver have the highest regenerative ability, followed by bone and muscle whereas heart, 
ligaments and the brain have a low capacity (Schroeder, 2008). Reservoirs of specific stem 
cells can be found in these tissues (Meirelles et al., 2006). Only some of these tissues, for 
example blood, can be restored to their original state after injury, but most tissues can only be 
repaired but not completely restored (Metcalfe & Ferguson, 2007; Schroeder, 2008).  
 
2. Stem cells 
Stem cells are the basis for nature’s reparation system. They are found in several tissues and 
are capable of self-renewal and differentiation, both in vitro and in vivo, into different cell 
lineages. This means that when a stem cell divides, it may produce a new stem cell (self-
renewal) or a tissue or organ specific cell (differentiation). Even after long periods of inactivity, 
these unspecialized stem cells are capable of renewing themselves or be induced, under 
certain physiologic or experimental conditions, to become tissue or organ specific cells with 
specific functions. This ability to self-renew is essential in the organism for both the expansion 
of several tissue cells as well as cellular turnover and repair (Wei et al., 2013; Melton, 2014). 
Whereas, in vitro, most somatic cells display a finite number of replications prior to senescence 
or replicative arrest (Hayflick & Moorhead, 1961; Hayflick, 1965; Cristofalo et al., 2004; Melton, 
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2014), stems cells exhibit a seemingly unlimited proliferative capacity. In vivo, stem cells exhibit 
sufficient proliferative capacity to last throughout the lifetime of the organism (Melton, 2014). 
In some tissues of postnatal mammals, such as bone marrow, muscle, and brain, discrete 
populations of adult stem cells exist. They self-renew and differentiate into a number of 
specialized cells formed by these tissues to generate replacements for cells that are lost 
through normal wear and tear, injury, or disease (Meirelles et al., 2006; El-Hashash, 2016). In 
some organs, such as the gut and bone marrow, stem cells regularly replicate to repair and 
replace worn out or damaged tissues whereas in other organs, namely the pancreas and the 
heart, stem cells only divide under specific conditions (Bhattacharyya & Khanduja, 2010). 
Until recently, research was done mainly with two kinds of stem cells from animals and humans: 
pluripotent embryonic stem cells (ESCs) and multipotent non-embryonic or adult stem cells 
(ASCs), as the cells used in this study. ESCs have certain ethical limitations, as well as the risk 
of teratoma formation whereas ASCs have a more limited differentiation potential (Salem & 
Thiemermann, 2010). Researchers have now developed genetically reprogrammed multipotent 
adult cells that function like embryonic stem cells; these are called induced pluripotent stem 
cells (iPSCs), from mouse and human adult stem cells. These are capable of generating cells 
characteristic of all three germ layers; the ectoderm, mesoderm and endoderm but as with 
ESCs, they also pose the risk of teratoma formation (Hou et al., 2013; Wei et al., 2013; Ross & 
Akimov, 2014). 
 
3. Mesenchymal stem cells  
Mesenchymal stem cells (MSCs) are a highly investigated population of stem cells, due to their 
unique biological properties, that were first isolated from bone marrow and characterized by 
Friedenstein and his colleagues (Afanasyev et al., 2009). They are multipotent stem cells, found 
in both embryonic and postnatal mammals, with differentiation potential towards mesoderm-
derived lineages (i.e., adipogenic, chondrogenic, myogenic, and osteogenic) (Caplan & Dennis, 
2006; Dominici et al., 2006). 
It has been found that not only do they have the ability and potential to differentiate into 
adypocytes, chondrocytes, myocytes and osteoblasts but also neurons, hepatocytes and 
pancreatic islet cells (Squillaro et al., 2016). Recent studies suggest that the differentiation 
capabilities of MSCs into diverse cell types vary between those of different origins. 
MSCs from different species and/or sources share the same primary characteristics and have 
similar morphology, yet clear differences in functional features have been verified in MSCs 
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isolated from synovial fluid versus bone marrow, as well as differences between species, such 
as ovine and equine were demonstrated (De Schauwer et al., 2014; Hillmann et al., 2016). 
Although the golden standard as a source of MSCs for research continues to be the bone 
marrow, since bone marrow derived MSCs are the most investigated and hence the best 
characterized of this cell type, other sources of MSCs are now being used (Fortier & Travis, 
2011; Mafi et al., 2011; Giai Via et al., 2012), such as dental pulp and synovia as was the case 
in this study. 
 
Sources of Mesenchymal stem cells 
MSCs can be found and isolated from several tissues in postnatal mammals, such as bone 
marrow (where they were originally identified), adipose tissue, peripheral blood, skeletal muscle, 
olfactory mucosa, synovium, dental pulp and hair follicles, as well as from fetal (i.e., bone 
marrow, liver, blood), and extraembryonic tissues (i.e., placenta, amnion) (DiMarino et al., 2013; 
Wei et al., 2013; Taran et al., 2014). Once isolated, they may be proliferated, expanded, 
differentiated and preserved in vitro. 
Since different methods of isolation and expansion of MSCs are used by researchers, it became 
necessary to characterize the cells and create standards to define human MSCs for both 
laboratory-based scientific investigations and for pre-clinical studies. To be classified as MSCs 
they must obey certain minimal criteria such as: they must be plastic-adherent when maintained 
in standard culture conditions using tissue culture flasks, ≥ 95% of the MSC population must 
express certain surface antigens and lack expression of others and finally, the cells must be 
able to differentiate to osteoblasts, adipocytes and chondroblasts under standard in vitro 
differentiating conditions (Dominici et al., 2006). Although Dominici’s paper served to 
characterize human MSCs, this also became the standard for characterizing mammalian MSCs 
and served as a basis for extrapolation to other species. 
 
4. Cell therapy and the uses and applications of Mesenchymal stem cells 
When Friedenstein et al. first described and isolated MSCs from bone marrow, showing their 
multipotent capacities to form bone, cartilage, and adipose tissue, they gave us the ingredients 
to explore the possibility of using these cells for regenerative medicine (Afanasyev et al., 2009).  
MSCs are advantageous over other stem cells types in regenerative medicine due to a variety 
of reasons making them, at present time, the most commonly used adult stem cells, and our 
cells of choice in this study. As previously mentioned, they avoid the ethical issues surrounding 
ESCs and are easily obtainable in sufficient quantities with minimal invasive methods since they 
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are present in several different tissues of postnatal mammals. Due to this, they are a well-
characterized population of adult stem cells and researchers now have advanced knowledge on 
how to grow them in culture and protocols for their isolation, expansion, and differentiation have 
been established. Isolation of MSCs and their in vitro maintenance has had increasing 
application in both experimental and clinical setups, owing to their easy isolation, high 
expansion properties in addition to their reproducible results. The idea that the infusion of MSCs 
might benefit organ and tissue repair given their ability to differentiate into cells of the targeted 
tissue and replace damaged resident cells has been sustained by several studies (Squillaro et 
al., 2016).  
So far, advancements in MSCs research show how these cells may have several clinical 
applications in both immunological disorders, such as prevention of graft-versus-host disease, 
and non-immunological disorders, and cell replacement therapies for mesenchymal tissues, for 
instance, bone and cartilage (Wei et al., 2013; Ikebe & Suzuki, 2014; Lane et al., 2014; 
Squillaro et al., 2016). It has also been demonstrated that local infusion is the preferred method 
of administration to take advantage of their differentiation potential since following systemic 
injection most MSCs are trapped in capillary beds of various tissues, especially the lungs 
(Squillaro et al., 2016). 
In recent years, some medical and biological issues such as rejection of donor stem cells by the 
patient’s immune system have arisen (de Almeida et al., 2013; Tang et al., 2013) but appear to 
be close to being solved by new cell therapies which will also help in solving transplant organ 
rejection. Mesenchymal stem cells also seem to be the core solution for this problem due to 
their immunomodulatory response reducing both the risks of rejection and complications of 
cellular, tissue and organ transplantation (Salem & Thiemermann, 2010; Taran et al., 2014). 
The ultimate goal for applying stem cell research is the cure of fatal or debilitating diseases in 
both humans and other animals. The search for the application in the eradication of malignant 
stem cells (cancer cells) and the cure for HIV/AIDS in humans is ongoing. The possibility of 
nervous system regeneration opens the door for cell therapies of both neurodegenerative 
conditions as well as spinal cord injuries, and the cure of other motor neuron and demyelinating 
diseases (Taran et al., 2014). 
To date there are 340 MSC-based clinical trials either complete or ongoing (obtained from 
https://clinicaltrials.gov/) worldwide. 
In clinical veterinary medicine, so far, stem cells are most commonly used in the treatment of 
musculoskeletal injuries of horses and dogs. Small and large animal species also serve as 
valuable models for preclinical evaluation of stem cell applications in human beings and in 
veterinary patients in areas such as spinal cord injury and myocardial infarction. There are also 
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new technologies of assisted reproduction undergoing development to apply the properties of 
spermatogonial stem cells to preserve endangered animal species (Fortier & Travis, 2011). 
 
5. Cryopreservation of mammalian cells  
The first mammalian cells to be cryopreserved successfully were spermatozoa in 1949 by Polge 
and his team (Polge et al., 1949). Since then, many methods and protocols have been 
developed for various types of cells, tissues and organs.  
The preservation of cells is an extremely important aspect of cell culture and the only effective 
means of preservation of animal cells is by freezing. Cryopreservation is a method whereby 
cells are frozen, maintaining their viability, until they are defrosted or thawed. Increased 
understanding of the causes of cryoinjury has continually led to improve cryopreservation 
methods and much progress in the field. 
The main reasons and advantages for the cryopreservation of cells are: 
- to avoid loss by microbial contamination 
- to reduce risk of cross contamination with other cell lines 
- to minimize genetic change in continuous cell lines (prone to genetic drift and 
morphological changes) 
- to enable storage of stocks of cells preventing the need to have all cell lines in culture at 
all times (which is invaluable when dealing with cells of a limited life span) 
- to carry out studies at a consistent and known passage number 
- to avoid aging and transformation into finite cell lines (fated for senescence) 
By careful preparation and strict procedures, once at ultralow temperatures, cells are 
biologically inert and can be maintained viable in this way for many years (typically ten years or 
more). 
The basic principle for success when cryopreserving and thawing cells is a slow freeze and a 
quick thaw. As a general guide, cells should be cooled at a rate of -1ºC to -3ºC per minute and 
thawed quickly by incubation in a water bath for 1-2 minutes (Liu et al., 2010; Hunt, 2011; 
Martinello et al., 2011). This principle was respected in this study and this procedure followed. 
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III. RESEARCH AIM 
The use of MSCs has spread worldwide and its importance has gained recognition in the past 
30 years. Therefore, it has become essential to establish well documented protocols for each 
step of the cell-based therapies, including their preservation.  
In general terms, it isn’t possible to follow every step required in cell-based treatments, from the 
harvest and isolation of MSC through their expansion to their final administration, without the 
need to cryopreserve, making this a vital step (Liu et al., 2010).  
Although there are reasonably well established and reproducible protocols for the 
cryopreservation of human stem cells in general (Hunt, 2011), there is a lack of confirmed 
cryopreservation protocols for stem cells of other mammals and of different sources (Mitchell et 
al., 2015). Nonetheless, even with established protocols, there is always room for improvement 
especially in light of new technologies, that are constantly becoming more readily available, and 
of new research results. Additionally, a very useful and significant data is that of the total loss of 
cell number and viability that occurs post cryopreservation and thaw processes.  
Therefore, the main aim of this study was to improve MSCs cryopreservation and thawing 
protocols using MSCs of three different sources; canine synovia (cSM), canine dental pulp 
(cDP) and rat synovia (rSM). 
In order to achieve the aim of this study, four main objectives were proposed as described 
below and shown in figures 1a), 1b) and 1c): 
 
- Improve cryopreservation protocols of MSCs by using two different media supplements, 
fetal bovine serum and  human umbilical cord blood plasma (UCBP) at different 
percentages 90 and 95%; 
- Determine the best thaw method for cryopreserved MSCs by thawing the samples using 
two different protein sources, canine serum and UCBP; 
- Define the optimum preservation temperature of thawed MSCs over time;  
- Establish the best vial material for conservation and transportation of thawed MSCs 
comparing results using plastic and glass vials. 
 
To determine cell viability the trypan blue exclusion test of cell viability was performed on each 
sample. 
In light of constant arising of new technologies and preclinical research results it is always 
possible to perfect existing cellular preservation techniques and that is what was attempted 
here. 
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Figure 1a) – Schematic representation of the experiments performed on the rSM MSCs sample. 
 
 
 
 
Figure 1b) – Schematic representation of the experiments performed on the cDP MSCs sample. 
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Figure 1c) – Schematic representation of the experiments performed on the cSM MSCs sample. 
 
Cell viability assay 
To evaluate cell viability, the trypan blue exclusion test of cell viability was performed. A 1:1 
dilution of the suspension was prepared by mixing 10µl of the cell suspension with 10µl of a 
0.4% trypan blue solution and then filling the Countess™ II FL reusable glass slide. The viability 
of the total number of cells (a percentage of the viable unstained cells in suspension related to 
the total number of cells counted) was obtained by reading the slide in a Countess® II FL 
Automated Cell Counter (Thermo Fisher Scientific). 
For each reading of the samples, four different fields of the slide were read and the mean of the 
percentage of viable cells was calculated. 
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Statistical analysis 
All statistical tests were performed with GraphPad Prism version 6.00 for Mac OS X (GraphPad 
Software, La Jolla California USA). 
In each sample reading, data were taken in quadruplicates. Data were presented as mean ± 
standard error of the mean (SEM). The SEM is an indication of the reliability of the mean. The 
smaller the SEM, the more accurate the sample mean as a reflection of the actual population 
mean. 
Probabilities of significant differences were performed using ANOVA with a significance level of 
0.05 and with p<0.05 to be considered statistically significant. 
 
 1. Cryopreservation of MSCs of different sources 
One of the objectives of this study was to compare the cryopreservation of MSCs of three 
different sources, canine synovial (cSM) MSCs, canine dental pulp (cDP) MSCs and rat synovial 
(rSM) MSCs, using two different protocols, with either fetal bovine serum (FBS) or human 
umbilical cord blood plasma (UCBP), at a final concentration of 90 or 95% (figures 1a)-1c)). 
Synovial MSCs are an attractive cell source due to their high expansion and chondrogenic 
potentials when compared to MSCs of other sources (Nakagawa et al., 2015). They require 
minimally invasive harvesting techniques and can be used in autologous stem cell therapies 
(Hatakeyama et al., 2017). 
Dental pulp MSCs, also represent an interesting adult stem cell source since they are easily 
recovered in large amount in a non-invasive manner from teeth extracted during routine dental 
procedures (Collart-Dutilleul et al., 2015; Potdar & Jethmalani, 2015) and have been isolated 
from several different species including humans (Iohara et al., 2006; Cheng et al., 2008; Alge et 
al., 2010; Mrozik et al., 2010; Nakatsuka et al., 2010; Potdar & Jethmalani, 2015). Another 
reason that makes them an interesting source involves their multipotent capabilities and the 
high plasticity they exhibit (Ledesma-Martínez et al., 2016).  
The most frequent method for cryopreserving mammalian cells minimizing cryoinjury is by 
storing them in liquid nitrogen in complete medium comprising of basal medium supplemented 
with 10-20% FBS or solely in FBS, and in the presence of a cyoprotective agent (Martinello et 
al., 2011; Naaldijk et al., 2012). Our intention was to measure the effects of the use of two 
different media supplements, FBS and UCBP, at different supplementation concentrations (90 
or 95%) and indirectly the use of low concentration of DMSO (10 or 5% respectively), on cellular 
number and viability . 
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The medium serves as a protein source for the cells and for the stabilization of the cell 
membrane during the crystallization process throughout the freezing or thawing process. FBS 
also acts as a protein shield for the toxic action of dimethyl sulfoxide (DMSO) in the early or late 
stages of the freezing and thawing processes, respectively (Liu et al., 2010). 
FBS is still used as a standard media supplement for animal cell expansion and 
cryopreservation since it is a low-cost and easily to obtainable supplement that provides an 
optimal culture medium. It contains an abundance of proteins, growth factors, enzymes and 
other chemical components that make it ideal for exceptional growth enhancement (Ikebe & 
Suzuki, 2014).  
Serum is the liquid portion of the blood after coagulation has occurred, thus fibrin and fibrin 
associated proteins are not present in serum. UCBP is an alternative to FBS as a media 
supplement but being plasma, and contrary to FBS, it still contains anti-coagulants and thus 
retains the proteins involved in the coagulation cascade. 
Our cryopreservative of choice was DMSO at a final concentration of 5 or 10% accordingly. 
Cryoprotective agents reduce the freezing point of the medium and also allow a slower cooling 
rate, greatly reducing the risk of ice crystal formation, which can damage cells by rupture and 
cause cell death. The detergent action of the DMSO increases cell membrane permeability, 
increasing its resistance rupture from ice crystals formation (Liu et al., 2010). This study also 
served to indirectly evaluate the use of low DMSO concentrations. 
 
a)   Materials and Methods 
Prior to cryopreservation, cellular concentration was determined by trypan blue staining using a 
Countess® II FL Automated Cell Counter (Thermo Fisher Scientific). The MSCs were 
resuspended in a solution containing either FBS at 90 or 95% or UCBP at 90 or 95% with a final 
concentration of DMSO of 5 or 10% accordingly. The cells were then aliquoted into cryogenic 
storage vials at a concentrations of 0.25 x 106 cells/ml (rSM and cDP) and 1 x 106 cells/ml 
(cSM) to be frozen slowly at 1°C/min. The vials, containing 1ml each, were placed in a pre-
cooled Mr. Frosty® Cryo 1°C Freezing Container (Nalgene®), appropriately filled with 100% 
isopropyl alcohol and subsequently placed in a -80°C freezer. They were left undisturbed for a 
minimum of 4 hours and finally the cryovials were transferred to permanent, long-term liquid 
nitrogen storage, at -195.8ºC, until needed.  
The samples remained cryopreserved in liquid nitrogen storage for a minimum of 9 days and a 
maximum of 30 days before being thawed and cell viability was assessed by trypan blue 
staining method immediately after thawing and removal of freezing solutions. 
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Good laboratory practices were followed at all times, from harvesting to cryopreserving the 
cells, to avoid contamination of the samples as well as cross-contamination of cell lines avoiding 
the need for the use of antibacterial and anti-mycotic agents.  
 
b)   Results and discussion 
To interpret the effects of the two different media supplements, FBS or UCBP, at the different 
concentrations of 90 and 95% on post-thaw viability, the viability results immediately post-thaw 
with canine serum into plastic vials at 0 hours of all three sample sources, must be compared.  
The viability results of rat synovia MSCs, canine dental pulp MSCs and canine synovia MSCs 
are shown in table 1 as well as represented in figures 2, 8 and 9.  
 
 
 
 
 
 
Table 1 – Post-thaw viability mean and SEM of rSM, cDP and cSM samples. Results are given as a percentage (%). 
 
From these results, there appears to be better thawing results with the rSM samples that were 
cryopreserved with FBS at 90% and those with UCBP at 95%, when compared to those 
cryopreserved with FBS 95% and UCBP 90% yet they were not statistically significant.  
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rSM was the first batch used to perfect our technique so their results cannot be taken too much 
into account, since a proper thawing and counting technique had not been previously 
established. 
In the cDP sample, on the other hand, cryopreservation with UCBP at 95% appears to yield the 
highest viability at 100±0% upon thawing but again these results were not statistically 
significant. 
The cSM sample does not have statistically significant differences and that comes through in 
the results represented in table 1 since they are quite evenly distributed. 
Therefore, there appears to be no effect on the viability of MSCs of these three sources upon 
cryopreserving with either FBS or UCBP at either 90 or 95%.  This is quite useful information for 
it allows laboratories to choose either supplement according to its availability, price or shelf-life 
without compromising cell viability. 
 
2. Thaw method 
It is known that the thawing procedure is stressful to cryopreserved cells and they may be 
harmed in the process thus reducing cell viability and cell numbers. Several protocols have 
been established for this process with the purpose of preserving as many cells as possible but it 
has yet to be determined the exact cell viability loss during the process as well as the best 
method yet so we are left with room for improvement (Mitchell et al., 2015). 
Canine serum and UCBP were compared as different protein sources during the thawing 
process and for post-thawed cells; one is a xenogeneic source or protein (UCBP), whereas 
when canine serum is used with the cDP and cSM samples, we are using an allogeneic protein 
source. This may present as an advantage since if xenogeneic protein sources have proven to 
be useful in this procedure, allogeneic sources should prove to be even more so. 
It is very important to work quickly and follow good laboratory practices. 
 
a)   Materials and Methods 
Each cryovial containing the cryopreserved cells, was removed from liquid nitrogen storage and 
immediately placed in a 37ºC water bath. The cryopreserved cells were then rapidly thawed, 
during 1 to 2 minutes, by gently swirling the vial in the 37ºC water bath until about 80% was 
defrosted, leaving just a small bit of ice left in the vial. This was necessary to avoid DMSO’s 
cytotoxicity. 
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The thawed cells were then washed with pre-warmed canine serum or UCBP and phosphate 
buffered saline (PBS). This step is important to wash off the cytotoxic DMSO. The cell 
suspension was then centrifuged at 1600 rpm for 10 minutes to remove any residual DMSO. 
After the centrifugation, the clarity of the supernatant was checked and a complete pellet 
identified. The supernatant was then aseptically decanted without disturbing the cell pellet. 
The cells were then gently resuspended in canine serum or UCBP accordingly, and divided into 
the necessary number of aliquots with 200-300µl each. 
 
b)   Results and discussion 
There were two different protein sources used during the thawing process of the cSM samples, 
canine serum and UCBP. Each sample that was cryopreserved using either 90 or 95% FBS and 
90 or 95% UCBP was thawed using canine serum (allogeneic) or UCBP (xenogeneic) as 
demonstrated in figure 1c).  
Those thawed into plastic vials and at 0 hours post-thaw are compared amongst themselves, as 
well as those thawed into glass vials and at 0 hours post-thaw (table 2). These results are also 
represented in figure 2. 
 
This was not done for the rSM or cDP samples, those were only thawed with UCBP. 
 
 
 
Table 2 - Post-thaw viability means and SEM values of cSM samples thawed using canine serum and UCBP into 
plastic vials (above) and glass vials (below). Results are given as a percentage (%). 
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Figure 2 – Plotting of cSM viability values for all samples at 0 hours. Canine synovial mesenchymal stem cells (cSM); 
fetal bovine serum (FBS); plastic (P); glass (G); canine serum (AS); human umbilical cord plasma, (UCBP, UP); 90% 
and 95% (90 and 95 respectively). 
 
When comparing the corresponding viability values directly of the samples thawed using canine 
serum with those thawed using UCBP into either the plastic vials or the glass vials, there appear 
to be slightly better results with the samples thawed with UCBP in detriment of those thawed 
with canine serum, yet there were no statistically significant differences. UCBP viability results 
remained above 96.50±0.9962% whereas canine serum values went as low as 93.67±1.176%. 
The highest viability results for UCBP were 99.42±0.1930% whereas canine serum results 
managed to reach 99.50±0.3371%. 
This being the case, canine serum could prove to be an adequate protein source for thawing 
cryopreserved canine MSCs. In light of these results, it would be useful to preform further 
thawing assays with canine MSCs from other sources for comparison as well as confirmation. If 
canine serum does prove to be an adequate protein source, the choice between using canine 
serum or UCBP would come down to a question of availability and costs. Given the possibility of 
the use of autologous serum, costs could be reduced since it is more readily available as blood 
may be collected from the same animal the MSCs are obtained from and at the same moment.  
Also, serum, contrary to plasma, does not require the addition of anticoagulants thus reducing 
costs further. Costs are always an issue in laboratory settings as well as costs of the final 
therapy so wherever they may be reduced is always a plus. 
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3. Vials and post-thaw preservation of the cSM samples 
There are many different vials on the market for use in the laboratory and they may vary 
significantly in price. Nonetheless, they are all generally made of one of two materials: glass or 
plastic. Also, depending on their material, their shape may vary making them easier to work with 
or not. 
The purpose of preparing two aliquots in different vial materials of the cSM MSC samples was 
to establish whether the material the MSCs were preserved in post-thaw interfered with the 
cellular viability. This was done over a 72 hour period.  
This was not done for the rSM or cDP samples, they were thawed into plastic vials only. 
The determination of the best temperature at which canine MSCs should be preserved post-
thaw, is equally important, since in most clinical settings, especially in veterinary medicine, a 
laboratory isn’t always handy next to the patient we are trying to treat, nor is it viable to transport 
the patient to the laboratory so that the treatment may be applied. Therefore, medicine and 
other therapeutic substances must be conditioned for transportation without a significant 
alteration of their properties. This is the information we hope to obtain from this trial. 
 
a)   Materials and Methods 
For the cSM samples, after being thawed with either canine serum or UCBP, six aliquots were 
prepared, three in glass vials and three in plastic vials and then one vial of each material was 
placed at each of the following temperatures: 4ºC (refrigeration), 21ºC (room temperature) and 
37ºC (incubation). 
Readings were taken at 0, 2, 4, 24, 48 and 72 hours post-thaw. 
 
b)   Results and discussion 
At 0 hours post-thaw, there is no statistical significant difference between the results of the 
plastic or glass vials, as mentioned above. This is as expected since at 0 hours the vial material 
did not have the time to interact with the cell suspension and affect viability values. This can be 
seen in tables 2 and figure 2 above. Nonetheless, there is no apparent or statistical difference in 
viability throughout the 72 hours when comparing the results of either vial. 
 
Differences do become apparent in the viabilities of the different temperature settings, 
particularly from 4 hours onwards. It becomes clear that viability is markedly compromised over 
time in the samples preserved at 37ºC (incubation) reaching values as low as 22±11.733% at 
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72 hours post-thaw (figure 4). In contrast, samples preserved in refrigeration at 4ºC maintain 
viability levels higher, only going as low as 83±0.913% at 72 hours post-thaw as can be seen in 
figure 6 below. 
 
Figure 3 – Viability values (mean±SEM) post-thaw and over 72 hours for the cSM samples cryopreserved with 
FBS90. Canine synovial mesenchymal stem cells (cSM); fetal bovine serum (FBS); plastic (P); glass (G); canine 
serum (AS); human umbilical cord plasma, (UCBP, UP); 90% (90). 
 
Figure 4 – Viability values (mean±SEM) post-thaw and over 72 hours for the cSM samples cryopreserved with 
FBS95. Canine synovial mesenchymal stem cells (cSM); fetal bovine serum (FBS); plastic (P); glass (G); canine 
serum (AS); human umbilical cord plasma, (UCBP, UP); 95% (95). 
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Figure 5 – Viability values (mean±SEM) post-thaw and over 72 hours for the cSM samples cryopreserved with 
UCBP90. Canine synovial mesenchymal stem cells (cSM); plastic (P); glass (G); canine serum (AS); human umbilical 
cord plasma, (UCBP, UP); 90% (90). 
 
 
Figure 6 – Viability values (mean±SEM) post-thaw and over 72 hours for the cSM samples cryopreserved with 
UCBP95. Canine synovial mesenchymal stem cells (cSM); plastic (P); glass (G); canine serum (AS); human umbilical 
cord plasma, (UCBP, UP); 95% (95). 
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Also, during the study, in the samples thawed with canine serum, agglomerates of viable cells 
(as those shown in figure 7 below), were seen in more or less quantity and size throughout the 
samples during the cell viability assay in each reading. This may have rendered the viability and 
total cell readings inaccurate. They were more present and of larger size in the samples 
maintained at 37ºC especially after 4 hours which is probably the reason why there was an 
increase in the SEM value (as seen in figures 3-6), indicating that the readings might not be 
very precise. 
 
 
 
 
 
 
 
 
Figure 7 – Agglomerates of viable cells observed while accessing cell viability in cSM samples thawed with canine 
serum. 
This is important since when samples were evaluated in the previous point (2. Thaw method), at 
0 hours, immediately post-thaw, agglomerates we not visible leading one to think of canine 
serum as an eligible protein source during the thaw process. If focusing only on the statistical 
data obtained at that time, there would appear to be no important differences between the 
results from the canine serum and the UCBP immediately post-thaw. 
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Observing the agglomerates it becomes unclear whether the canine serum could be suitable in 
the thawing process. The reason for the formation of agglomerates must be investigated further 
since this might hold back the use of a cheap and readily available allogeneic source of protein 
and an autologous source may be required.  
Also, in a previous study by Mitchell and his team in 2015 equine allogeneic serum was used 
during the cryopreservation stage and similar results to cryopreserving with FBS were obtained.  
This might be an indication that it is also possible to use allogeneic serum during the thawing 
process but further experiments must be conducted. There is no mention of the formation of 
cellular agglomerates so the reason for this to have happened in our study should be explored. 
A possible reason for this may reside in the fact that Mitchell and his colleagues used 
commercial serum that might have been subjected to certain processes, eliminating antibodies 
for example, whereas non-commercial serum collected in house was used here. 
Autologous protein sources are a very interesting possibility, even more than allogeneic 
sources, since it may allow for serum to be collected together with of the collection of the MSCs, 
from a specific individual. This may serve to reduce costs, allowing for the serum to be stored 
for use later on in the process, as well as maybe reduce rejection reactions since both MSCs 
and serum would be from the same origin.  
 
4. Post-thaw preservation of the rSM and cDP samples 
As mentioned previously, it is just as imperative as the previous determinations to conclude the 
optimum temperature at which cells must be conserved after undergoing cryopreservation and 
subsequent thawing process, and for how long, in order to maintain a high viability and cell 
number, so that they can be applied at a later time.  
This determination will enable calculation of the quantity of viable cells needed to be 
cryopreserved so that an exact number be recovered after the thawing process and transferred 
to the animal being treated. Furthermore, it will allow us to determine the best conservation 
method post-thaw until the cells can be administered to the patient maintaining the highest 
number of cells and viability possible, increasing the ‘window of opportunity’ to allow for the 
transportation of therapeutic doses from the preparation facilities to the clinic or application site 
(in the case of ambulatory application). 
Three different temperature settings were tested, refrigeration at 4ºC, room temperature at 21ºC 
and incubation at 37ºC for the rSM and cDP MSCs samples over a period of 24 hours. 
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a)   Materials and Methods 
Three aliquots of each rat synovia and canine dental pulp MSCs samples (90 and 95% FBS and 
90 and 95% UCBP) were prepared as described previously and then placed at different 
temperatures: one at 4ºC in refrigeration, another at 21ºC room temperature and the third 
incubated at 37ºC over a period of 24 hours for each of the samples. 
Readings were taken at 0, 2, 4 and 24 hours post-thaw. 
 
b)   Results and discussion 
In the rSM samples (figure 8) cryopreserved with FBS at 95%, maintained at room temperature, 
there is an increase in viability from the 4 hour reading, 91±4.796SEM, to the 24 hour reading 
100±0% probably due to the dead, non-viable cells suffering lysis and therefore no longer being 
taken into account. The same happened with the rSM samples cryopreserved with FBS at 95% 
maintained at 4ºC and 37ºC. There are a few more inconsistencies of the like with the rSM 
samples cryopreserved with UCBP.  
The rSM samples were the first used in the study and served to establish thawing and counting 
procedures so their results might be inconsistent and compromised due to that.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Viability values (mean±SEM) post-thaw and over 24 hours for the rSM samples cryopreserved with 
UCBP95. Rat synovial mesenchymal stem cells (rSM); fetal bovine serum (FBS); human umbilical cord plasma, 
(UCBP, UP); 90 and 95% (90 and 95 respectively). 
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Otherwise, in the cDP samples (figure 9), there seems to more consistency in the viability 
percentage loss in each of the comparable samples where the samples cryopreserved in FBS 
90 and 95% preserved at 37ºC had a viability of only 85.5±4.992% and 87±1.472% at 24 hours 
respectfully whereas the equivalent samples preserved at 4ºC had a viability of 98.75±0.479% 
and 94±1.354% at the end of the 24 hours. In the same way, the samples cryopreserved in 
UCBP 90 and 95% preserved at 37ºC had a viability of 95±1.414% and 84.5±3.884% at 24 
hours respectfully whereas the equivalent samples preserved at 4ºC had a viability of 
96.5±0.957% and 97.250±1.031% at the end of the 24 hours. 
Similarly to what happened with the rSM samples, in some cDP samples there was an increase 
in the mean viability values from the 4 hour readings to the 24 hour readings, but there was also 
an increase in the SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Viability values (mean±SEM) post-thaw and over 24 hours for the rSM samples cryopreserved with 
UCBP95. Rat synovial mesenchymal stem cells (rSM); fetal bovine serum (FBS); human umbilical cord plasma, 
(UCBP, UP); 90 and 95% (90 and 95 respectively). 
In conclusion, and as shown in figures 3-6, 8 and 9, the viability loss of the samples maintained 
at 4ºC, over the 24 hour period, was generally lower than that of those maintained at 21ºC and 
37ºC being the latter the ones presenting the worst results, rendering statistically significant 
results. 
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VI. CONCLUSION 
It is clear that high and predictable survival rates for cell cultures are important due to the time 
consuming, costly and difficult preparation processes.  Consequently, methods used for cell 
cryopreservation must ensure the highest viability possible. 
There has been a large amount of developmental work undertaken to ensure successful 
cryopreservation and thawing of cell culture yet the basic principle of successful 
cryopreservation and thawing continues to be a slow freeze and quick thaw although there are 
other important factors that influence the rate of success such as the quality and type of 
reagents used and the work method. 
Besides the cryopreservation and thawing methods, other factors that can affect the viability of 
cryopreserved cells include growth conditions prior to harvesting, the physiological state of the 
cells and the cell density.  
As mentioned before, the purpose of this study was to improve cryopreservation and thawing 
methods as well as to establish the best preservation temperature of thawed MSCs over time 
enabling cells to be transported to their location of use without reducing their viability. 
It was possible to determine that regarding cryopreservation technique, there is no significant 
difference in loss of viability between using FBS or UCBP as a serum/protein and that 
supplementation of up to 95%, and only 5% DMSO may be used not compromising cell viability.  
During the thawing process, UCBP and canine serum presented similar results in viability 
leading one to conclude that canine serum might be an adequate protein source for the thawing 
process but once post-thaw viability was evaluated over time, it became clear that this was not 
so. The samples thawed with canine serum formed cellular agglomerates compromising them 
and ultimately one must conclude that UCBP might be a better choice. Nonetheless, there have 
been previous studies where allogeneic sources of protein source have rendered satisfying 
results and did not encounter these problems although they were used as a serum 
supplementation source during the cryopreservation process and not the thawing process. 
If the formation of agglomerates could be solved (for example by removing antigens) it would 
give leeway for laboratory choice of protein source depending on accessibility, costs and shelf-
life for example. A new protocol could be implemented where, at the same time as MSCs are 
collected, blood is drawn as to be used in the thaw process of those cells later on (an 
autologous source of serum) or of MSCs of other individuals of the same species (as an 
allogeneic source of serum). Further tests can be performed to conclude whether allogeneic 
serum is an acceptable protein source for this process in all species thus significantly reducing 
costs of acquisition of commercial reagents. 
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However, it became very apparent that when it comes to preserving cells post-thaw, the best 
method is to do so is at 4ºC, in refrigeration, or at least the lowest temperature possible since 
room temperature (21ºC) also yielded better viability results than incubation at 37ºC. This is 
extremely useful, especially in the veterinary field, where veterinarians must frequently travel to 
apply the therapies to their patients. It is important to know how long post-thaw cells will remain 
with an acceptable viability, above a desired percentage, so as to calculate the number of cells 
needed to be cryopreserved for a given treatment.  
This study still leaves room for improvement. A study with clear and separate experiments for 
each of the objectives of the present study would allow for a more clear and accurate 
interpretation of the results. As with any study, an increased amount of samples and readings is 
always beneficial and would allow for a diminution of the SEM value, rendering more accurate 
means. 
Also, each of these experiments done individually with total cells numbers together with 
viabilities would provide us with a lot of useful information since we may have a sample with 
100% viability but a significant reduction in the total cell number by cell lysis for example, or the 
formation of agglomerates as was the case in this study. 
Despite enthusiastic levels of interest in the field of cell therapy where MSCs are presenting to 
be of great use, the reality is that other than the use of haematopoietic stem cells, many other 
therapies have yet to be thoroughly proven for their therapeutic benefit and safety in application 
(Lin et al., 2013).  
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